JP2024529119A - 抗vegfaとvegfc二重特異性抗体およびその使用 - Google Patents
抗vegfaとvegfc二重特異性抗体およびその使用 Download PDFInfo
- Publication number
- JP2024529119A JP2024529119A JP2024508417A JP2024508417A JP2024529119A JP 2024529119 A JP2024529119 A JP 2024529119A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024529119 A JP2024529119 A JP 2024529119A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110932078 | 2021-08-13 | ||
| CN202110932078.7 | 2021-08-13 | ||
| PCT/CN2022/111717 WO2023016516A1 (zh) | 2021-08-13 | 2022-08-11 | 抗vegf a和vegf c双特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529119A true JP2024529119A (ja) | 2024-08-01 |
| JP2024529119A5 JP2024529119A5 (cg-RX-API-DMAC7.html) | 2025-08-15 |
Family
ID=85200580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508417A Pending JP2024529119A (ja) | 2021-08-13 | 2022-08-11 | 抗vegfaとvegfc二重特異性抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250002570A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4386004A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529119A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118043350A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022327397B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229250A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023016516A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024165077A1 (zh) * | 2023-02-10 | 2024-08-15 | 信达生物制药(苏州)有限公司 | 一种包含抗vegfa和vegfc双特异性结合蛋白的药物制剂 |
| WO2025250739A1 (en) * | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Chimeric antigen receptor with spacer domains derived from human igg |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008535819A (ja) * | 2005-03-25 | 2008-09-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegfアンタゴニスト製剤 |
| JP2012518400A (ja) * | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 多価および/または複数特異的rankl結合性構築物 |
| JP2013513383A (ja) * | 2009-12-11 | 2013-04-22 | ジェネンテック, インコーポレイテッド | 抗vegf−c抗体及びその使用方法 |
| US20150110787A1 (en) * | 2013-10-18 | 2015-04-23 | Samsung Electronics Co., Ltd. | Polypeptide specifically binding to vegf-c and use thereof |
| JP2018516546A (ja) * | 2015-04-24 | 2018-06-28 | ジェネンテック, インコーポレイテッド | 多特異性抗原結合タンパク質 |
| WO2020077169A1 (en) * | 2018-10-12 | 2020-04-16 | Trican Biotechnology Co., Ltd | Bi-functional fusion proteins and uses thereof |
| JP2020516287A (ja) * | 2017-04-11 | 2020-06-11 | インヒブルクス インコーポレイテッド | 制約されたcd3結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 |
| WO2020176815A2 (en) * | 2019-02-27 | 2020-09-03 | Zhejiang Nanomab Technology Center Co. Ltd. | Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution |
| CN112552412A (zh) * | 2019-12-05 | 2021-03-26 | 屈向东 | 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白 |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN112961250A (zh) * | 2021-03-01 | 2021-06-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
| JP2021516952A (ja) * | 2018-03-27 | 2021-07-15 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規な抗体分子、その調製方法及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403088B1 (en) * | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| CA2796205A1 (en) * | 2010-04-15 | 2011-10-20 | Vegenics Pty Limited | Combination treatment with vegf-c antagonists |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PH12014500220A1 (en) * | 2011-07-27 | 2019-03-22 | Glaxo Group Ltd | Anti-vegf single variable domains fused to fc domains |
| CN108640994A (zh) * | 2018-06-28 | 2018-10-12 | 浙江众意生物科技有限公司 | 一种vegf-c单克隆抗体及试剂盒 |
-
2022
- 2022-08-11 CN CN202280055810.XA patent/CN118043350A/zh active Pending
- 2022-08-11 CA CA3229250A patent/CA3229250A1/en active Pending
- 2022-08-11 JP JP2024508417A patent/JP2024529119A/ja active Pending
- 2022-08-11 WO PCT/CN2022/111717 patent/WO2023016516A1/zh not_active Ceased
- 2022-08-11 US US18/681,904 patent/US20250002570A1/en active Pending
- 2022-08-11 AU AU2022327397A patent/AU2022327397B2/en active Active
- 2022-08-11 EP EP22855496.0A patent/EP4386004A4/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008535819A (ja) * | 2005-03-25 | 2008-09-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegfアンタゴニスト製剤 |
| JP2012518400A (ja) * | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 多価および/または複数特異的rankl結合性構築物 |
| JP2013513383A (ja) * | 2009-12-11 | 2013-04-22 | ジェネンテック, インコーポレイテッド | 抗vegf−c抗体及びその使用方法 |
| US20150110787A1 (en) * | 2013-10-18 | 2015-04-23 | Samsung Electronics Co., Ltd. | Polypeptide specifically binding to vegf-c and use thereof |
| JP2018516546A (ja) * | 2015-04-24 | 2018-06-28 | ジェネンテック, インコーポレイテッド | 多特異性抗原結合タンパク質 |
| JP2020516287A (ja) * | 2017-04-11 | 2020-06-11 | インヒブルクス インコーポレイテッド | 制約されたcd3結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 |
| JP2021516952A (ja) * | 2018-03-27 | 2021-07-15 | イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド | 新規な抗体分子、その調製方法及びその使用 |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2020077169A1 (en) * | 2018-10-12 | 2020-04-16 | Trican Biotechnology Co., Ltd | Bi-functional fusion proteins and uses thereof |
| WO2020176815A2 (en) * | 2019-02-27 | 2020-09-03 | Zhejiang Nanomab Technology Center Co. Ltd. | Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution |
| CN112552412A (zh) * | 2019-12-05 | 2021-03-26 | 屈向东 | 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白 |
| CN112961250A (zh) * | 2021-03-01 | 2021-06-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| MABS, vol. 8, no. 8, JPN6026025578, 2016, pages 1467 - 1476, ISSN: 0005892144 * |
| PLOS ONE, vol. 5, no. 8, JPN6026025577, 2010, pages 11941, ISSN: 0005892143 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022327397B2 (en) | 2026-06-18 |
| AU2022327397A1 (en) | 2024-03-14 |
| WO2023016516A1 (zh) | 2023-02-16 |
| US20250002570A1 (en) | 2025-01-02 |
| CA3229250A1 (en) | 2023-02-16 |
| CN118043350A (zh) | 2024-05-14 |
| EP4386004A1 (en) | 2024-06-19 |
| EP4386004A4 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220235123A1 (en) | Synthetic antibodies against vegf and their uses | |
| JP5823858B2 (ja) | 抗vegf抗体 | |
| US20240247057A1 (en) | Bispecific binding molecule binding to vegf and ang2 and use thereof | |
| KR20210141992A (ko) | Vegf 및 ang2에 특이적으로 결합되는 이중특이적 항체 | |
| KR20140019375A (ko) | 인간 조직 인자 항체 및 이의 용도 | |
| KR20240004860A (ko) | 디엘엘3에 대한 결합 분자 및 이의 용도 | |
| US11008387B2 (en) | Antibody inhibiting binding of VEGF to NRP1 | |
| JP2024502091A (ja) | Pd-1結合分子およびその使用 | |
| US20260009804A1 (en) | Antibodies that bind to natively folded myocilin | |
| US20250002570A1 (en) | Anti-vegf a and vegf c bispecific antibodies and use thereof | |
| WO2024114746A1 (zh) | 包含结合VEGF和Ang2的双特异性结合分子的制剂以及其用途 | |
| KR20250139273A (ko) | 삼중특이적 융합 단백질 및 이의 용도 | |
| JP2026506572A (ja) | 抗vegfaおよびvegfc二重特異性結合タンパク質を含む医薬製剤 | |
| AU2021294703A1 (en) | Anti-ANG-2 antibody and use thereof | |
| TW202302641A (zh) | 針對IL-13Rα2的抗體及其應用 | |
| WO2025113639A1 (zh) | 抗gdf15的抗体及其方法和用途 | |
| WO2024188179A1 (zh) | 一种靶向ctgf的抗体或其抗原结合片段及其应用 | |
| JP2024506664A (ja) | 抗vegf抗体およびその使用 | |
| CN118791607A (zh) | 双特异性抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250806 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250806 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260623 |